Alpha-1 Antitrypsin Deficiency Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

DelveInsight's, "Alpha1-Antitrypsin Deficiency Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha1-Antitrypsin Deficiency pipeline landscape. It covers the Alpha-1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alpha-1 Antitrypsin Deficiency pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Alpha-1 Antitrypsin Deficiency Treatment Drugs @ Alpha-1 Antitrypsin Deficiency Pipeline Report- https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Alpha-1 Antitrypsin Deficiency Pipeline Report
• July 2024:- Sanofi- Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. This is a Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.
• April 2024:- Krystal Biotech Inc announced a study of Phase 1 clinical trials for KB408 (Nebulization). This study is designed to evaluate safety and pharmacodynamics of KB408 in adults with AATD with a PI*ZZ genotype. Three planned dose levels of KB408 will be evaluated in single dose escalation cohorts. Subjects taking intravenous AAT augmentation therapy are not required to wash out from IV AAT in the low and mid dose cohorts. At the high dose, two cohorts will be conducted in parallel to evaluate patients on and off IV augmentation therapy.
• March 2024:- Takeda announced a study of Phase 3 clinical trials for Fazirsiran Injection. A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis.
• DelveInsight's Alpha-1 Antitrypsin Deficiency pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha-1 Antitrypsin Deficiency treatment.
• The leading companies working in the Alpha-1 Antitrypsin Deficiency Market include Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
• Promising Alpha-1 Antitrypsin Deficiency Pipeline Therapies in the various stages of development include Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, ADVM-043, and others.

In the Alpha-1 Antitrypsin Deficiency pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Alpha-1 Antitrypsin Deficiency clinical trials, NDA approvals (if any), and product development activities comprising the technology, Alpha-1 Antitrypsin Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Alpha-1 Antitrypsin Deficiency Overview
Alpha-1-antitrypsin (AAT) is a protein produced in the liver that protects the body's tissues from being damaged by infection-fighting agents released by its immune system. In alpha-1 antitrypsin deficiency, the body's normal production of AAT is reduced, resulting in the destruction of sensitive lung tissue.

Find out more about Alpha-1 Antitrypsin Deficiency Therapeutics Assessment @ Alpha-1 Antitrypsin Deficiency Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alpha-1 Antitrypsin Deficiency Emerging Drugs Profile
• ARO AAT: Arrowhead Pharmaceuticals
• ALN-AAT02: Alnylam Pharmaceuticals

Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics Assessment
There are approx. 12+ key companies which are developing the Alpha-1 Antitrypsin Deficiency therapies. The Alpha-1 Antitrypsin Deficiency companies which have their Alpha-1 Antitrypsin Deficiency drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

DelveInsight's Alpha-1 Antitrypsin Deficiency pipeline report covers around 12+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Alpha-1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Alpha-1 Antitrypsin Deficiency Pipeline Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Alpha-1 Antitrypsin Deficiency Pipeline Therapies @ Alpha-1 Antitrypsin Deficiency Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Alpha-1 Antitrypsin Deficiency Pipeline Report
• Coverage- Global
• Alpha-1 Antitrypsin Deficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alpha-1 Antitrypsin Deficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Alpha-1 Antitrypsin Deficiency Companies- Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
• Alpha-1 Antitrypsin Deficiency Pipeline Therapies- Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, ADVM-043, and others.

Dive deep into rich insights for new drugs for Alpha-1 Antitrypsin Deficiency Treatment, Visit @ Alpha-1 Antitrypsin Deficiency Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Alpha-1 Antitrypsin Deficiency Executive Summary
3. Alpha-1 Antitrypsin Deficiency: Overview
4. Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics
5. Alpha-1 Antitrypsin Deficiency Pipeline Therapeutic Assessment
6. Alpha-1 Antitrypsin Deficiency- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ARO AAT: Arrowhead Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ALN-AAT02: Alnylam Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alpha-1 Antitrypsin Deficiency Key Companies
21. Alpha-1 Antitrypsin Deficiency Key Products
22. Alpha-1 Antitrypsin Deficiency- Unmet Needs
23. Alpha-1 Antitrypsin Deficiency- Market Drivers and Barriers
24. Alpha-1 Antitrypsin Deficiency- Future Perspectives and Conclusion
25. Alpha-1 Antitrypsin Deficiency Analyst Views
26. Alpha-1 Antitrypsin Deficiency Key Companies
27. Appendix

For further information on the Alpha-1 Antitrypsin Deficiency Pipeline therapeutics, reach out to Alpha-1 Antitrypsin Deficiency Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Leptomeningeal Metastases Market: https://www.delveinsight.com/report-store/leptomeningeal-metastases-market
• Metabolic Acidosis Market: https://www.delveinsight.com/blog/metabolic-acidosis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Non Cystic Fibrosis Bronchiectasis Market: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-market
• Nontuberculous Mycobacteria Infection Market: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Postmenopausal Vaginal Atrophy Market: https://www.delveinsight.com/infographics/atrophic-vaginitis-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Sjogren's Syndrome Market: https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Treatment Resistant Depression Market: https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market
• Turner Syndrome Market: https://www.delveinsight.com/report-store/turner-syndrome-market
• Uncomplicated Urinary Tract Infections Market: https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
• Urolithiasis Market: https://www.delveinsight.com/report-store/urolithiasis-management-devices-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/ventricular-fibrillation-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.